Optimal glucocorticoid dose and the effects on mortality, length of stay, and readmission rates in patients diagnosed with acute exacerbation of chronic obstructive pulmonary disease (AECOPD)

Asim Kichloo, Michael Aljadah, Navya Vipparla, Farah Wani

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

The burden of acute exacerbation of chronic obstructive pulmonary disease (AECOPD) is staggering on a national and global level. Yet, surprisingly, there is a profound lack of treatment standardization with glucocorticoids in the treatment of AECOPD. In this review, we bring attention to specific literature that use a cut-off of 60 mg prednisone equivalent per day when distinguishing between high-dose and low-dose glucocorticoid treatment. We hope this review encourages future research to begin incrementally lowering the cut-off dose of 60 mg to discover if mortality, length of hospital stays, and readmission rates change between high-dose and low-dose glucocorticoid treatment. The final hope would be to establish an optimal glucocorticoid dose to treat AECOPD and eliminate treatment ambiguity.

Original languageEnglish
Pages (from-to)1161-1164
Number of pages4
JournalJournal of Investigative Medicine
Volume67
Issue number8
DOIs
StatePublished - Dec 1 2019

Keywords

  • chronic obstructive
  • pulmonary disease

Fingerprint

Dive into the research topics of 'Optimal glucocorticoid dose and the effects on mortality, length of stay, and readmission rates in patients diagnosed with acute exacerbation of chronic obstructive pulmonary disease (AECOPD)'. Together they form a unique fingerprint.

Cite this